Last reviewed · How we verify
NCT07116928: GLOW-CKD
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Phase 4 trial testing ganagliflozin in T2DM (Type 2 Diabetes Mellitus) in 1,244 participants. Not yet recruiting.
30 October 2031
Quick facts
| Lead sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 1,244 |
| Start date | 30 November 2025 |
| Primary completion | 30 October 2031 |
| Estimated completion | 30 December 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- ganagliflozin — full drug profile →
- Placebo
Conditions studied
- T2DM (Type 2 Diabetes Mellitus) — all drugs for T2DM (Type 2 Diabetes Mellitus) →
- CKD - Chronic Kidney Disease — all drugs for CKD - Chronic Kidney Disease →
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with T2DM (Type 2 Diabetes Mellitus) or CKD - Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07116928
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ganagliflozin
Trials testing the same drug.
- NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
Other recruiting trials for T2DM (Type 2 Diabetes Mellitus)
Currently open trials in the same condition.
- NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting
- NCT07005362 — Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D · recruiting
- NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
- NCT07172997 — Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
Other Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07502001 — Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin · Phase 1 · not yet recruiting
- NCT07521631 — Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes · Phase 2 · recruiting
- NCT07417306 — A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose · Phase 3 · not yet recruiting
- NCT07529782 — Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07394114 — A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07116928 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Last refreshed: 18 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07116928.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing